On April 8, 2022 Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, reported data demonstrating the Company’s CXCR3 chemokine receptor modulator, SG-3-06686 (referred to as SG-3-00802DC in the AACR (Free AACR Whitepaper) presentation), enhances effector T cell migration to improve the immune system’s activity against tumors, and showed anti-tumor activity in preclinical models as a monotherapy and in combination with anti-Programmed Death Protein-1 (PD-1) treatment (Press release, Second Genome, APR 8, 2022, View Source [SID1234611794]). The data is being presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, held April 8–13 virtually and in New Orleans, Louisiana.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are excited about our pre-clinical data that show the ability of this potential mechanism to go beyond checkpoint blockade as an emerging new immunologic strategy for treating cancers. Checkpoint inhibitor therapy has been transformative for the clinical outcome of cancer patients and additional new checkpoint targets, such as TIGIT/LAG3, continue to be added to this important treatment approach. However, if the proper immune cells are underrepresented or lacking in the tumor microenvironment, these interventions tend to be less effective, and a significant portion of patients have limited or transient benefit. To augment and improve anti-tumor efficacy, we need to develop new therapeutics to better facilitate the ability of effector cells to access the tumor microenvironment. CXCR3 pathway modulation is a well validated and exciting approach to potentially enhance effector cell recruitment and improve existing immunotherapy interventions," said Joe Dal Porto, Ph.D., Chief Scientific Officer of Second Genome. "We look forward to submitting an investigational new drug (IND) application for SG-3-06686, a potential first in class CXCR3 immune modulator, in early 2023."
This data presentation can be accessed during the online-only poster session at the AACR (Free AACR Whitepaper). The information is provided below:
Session Category: Clinical Research Excluding Trials
Session Title: Immuno-oncology
Abstract Number: 6349
Title: Targeting the CXCR3 pathway with a novel peptide drug candidate mobilizes the
immune system to enhance anti-tumor immunity
SG-3-06686 is a potent CXCR3 chemokine receptor engager that acts as a positive allosteric modulator to increase receptor activity to the three known ligands (CXCL9/10/11). It has demonstrated to increase the activity of CXCL11 on CXCR3 activation by greater than 10-fold from a nM to a pM range with similar effects on CXCL9 and CXCL10. This activity in turn drives strong antitumor activity in several preclinical cancer models.
The poster (#6349) entitled, "Targeting the CXCR3 pathway with a novel peptide drug candidate mobilizes the immune system to enhance anti-tumor immunity," will be available for on-demand viewing on the AACR (Free AACR Whitepaper) website and will also be made available on the Company’s website at View Source